DSS, Inc. filings document the company's public-company reporting, securities registrations, capital structure, and material events for a New York corporation with common stock listed on NYSE American. Registration statements cover common-stock offering mechanics, issuer classification, and Securities Act disclosure for financing activity.
Form 8-K filings report shareholder voting results, director elections, auditor changes, material agreements, debt-conversion arrangements involving Impact Biomedical, and other capital-structure matters. The filing record also includes audit and going-concern disclosure tied to annual reporting, along with governance and operating-result categories relevant to DSS's diversified segments.
DSS, Inc. (DSS) entered into a related-party securities purchase agreement with Alset Inc. under which Alset loaned DSS $500,000 in exchange for a convertible promissory note and warrants for up to 8,000,000 common shares. The note carries 3% simple interest and is payable on demand, with a five-year maturity.
Alset may convert principal and interest into common stock at $0.50 per share, and the warrants are exercisable at $0.55 per share for five years. Conversion of the note and exercise of the warrants both require stockholder approval. DSS and Alset are under common control through Chairman Chan Heng Fai, and the board and audit committee approved the transaction.
DSS, Inc. (DSS) is the subject of an amended Schedule 13D in which Heng Fai Ambrose Chan and affiliated entities report very high beneficial ownership of the company’s common stock. Chan is deemed to beneficially own 26,311,715 shares, representing 86.3% of DSS’s common stock under Rule 13d-3, based on 10,042,518 shares outstanding as of September 8, 2026.
Chan’s reported stake includes shares held directly and through Heng Fai Holdings Limited, Alset Inc., Alset International Limited, and Global Biomedical Pte. Ltd., as well as convertible promissory notes and warrants that are initially convertible or exercisable into additional DSS shares. On September 3, 2026, Chan sold 21,852 shares of DSS common stock at $0.82 per share, a relatively small transaction compared with the reported beneficial position.
DSS, INC. (DSS) director and ten percent owner Chan Heng Fai Ambrose reported a sale of 21,852 shares of common stock on September 3, 2026 at $0.82 per share in an open-market or private transaction. After this sale, he directly held 1,031,944 shares, with additional securities held indirectly through various entities.
DSS, Inc. (DSS) has filed a prospectus supplement for a primary offering of common stock and accompanying pre-funded warrants under its $10,000,000 shelf registration. The pre-funded warrants carry a de minimis exercise price of $0.00001 per share and are structured with ownership caps to limit any holder’s post-exercise beneficial ownership to 4.99% or, at the holder’s election, 9.99% of outstanding common stock.
The company’s public float, calculated under Form S-3 General Instruction I.B.6, is about $3.31 million based on 3,898,854 non‑affiliate shares at $0.85 per share as of September 3, 2026, and DSS states it has not used this S-3 capacity in the prior 12 months. DSS plans to use net proceeds, together with existing cash, for capital expenditures, operations, marketing, investments in existing initiatives and products, potential acquisitions, and general working capital. The filing highlights that investors in this offering will experience immediate and potentially substantial dilution and may face further dilution from future equity issuances and outstanding equity awards.
DSS, Inc. reports weaker results for the quarter and six months ended June 30, 2026. Total revenue for the quarter was $3.6 million versus $5.3 million a year earlier, and $7.9 million for the six-month period versus $10.2 million. The company recorded an operating loss of $3.8 million for the quarter and $9.3 million year-to-date, compared with $3.4 million and $7.2 million in the prior-year periods.
Net loss attributable to common stockholders widened to $4.8 million for the quarter and $10.4 million for the six months, with basic and diluted loss per share of $0.48 and $1.06, respectively. Cash and cash equivalents declined to $4.1 million, marketable securities to $2.8 million, and current assets to $9.4 million against current liabilities of $49.2 million, resulting in a reported negative working capital position of about $39.9 million. Management discloses that these conditions raise substantial doubt about the company’s ability to continue as a going concern and outlines plans relying on asset sales, additional financing, and cost reductions.
The balance sheet reflects significant debt, including approximately $38.5 million under a LifeCare real estate loan that is in default and past due. DSS also reports large credit loss reserves on notes receivable and continues to engage in related-party financing and investment transactions, including an equity method investment in True Partners Capital Holding Limited and convertible financing arrangements with Alset-affiliated entities. As of August 5, 2026, there were 10,042,518 common shares outstanding.
DSS, INC. reported an indirect restructuring-type transaction involving entities associated with director and ten percent owner Chan Heng Fai Ambrose. Alset International Limited holds a $2,450,000 Convertible Promissory Note that became convertible into common stock at $0.74 per share on June 3, 2026. On March 26, 2026, Alset International Limited also received common stock purchase warrants to buy up to 16,554,055 DSS common shares at an exercise price of $0.93 per share, expiring on March 26, 2031. The filing notes these positions as indirectly beneficially owned through entities controlled by Mr. Chan.
DSS, Inc. received an updated ownership report showing that Heng Fai Ambrose Chan and his affiliated entities now beneficially own 26,464,246 shares and related derivatives, representing 86.8% of DSS common stock. This percentage is based on 10,042,518 shares outstanding as of July 9, 2026.
The position includes a $2,450,000 convertible promissory note issued to Alset International Limited, initially convertible at $0.74 per share, and common stock purchase warrants to buy up to 16,554,055 shares at $0.93 per share expiring on March 26, 2031. These instruments give the Alset group significant additional potential ownership beyond current common shares.
DSS, Inc. entered into a material definitive financing agreement with Alset, Inc., under which Alset will loan DSS $1,000,000 in exchange for a convertible promissory note and stock warrants.
The note carries simple interest of 3% per year and matures five years from issuance. Alset may convert principal and accrued interest into DSS common stock at $0.45 per share. Separately, Alset receives warrants to purchase up to 17,777,776 DSS shares at an exercise price of $0.50 per share, expiring three years from issuance.
The deal is a related party transaction because DSS and Alset are under common control of Chan Heng Fai and share overlapping directors. The agreements were approved by DSS’s board and, where applicable, its audit committee, with interested directors recusing themselves.
DSS, Inc. reported a larger net loss for the quarter ended March 31, 2026 and raised substantial doubt about its ability to continue as a going concern. Revenue fell to $4.33 million from $4.95 million a year earlier, while cost of revenue and higher selling, general and administrative expenses drove an operating loss of $5.49 million versus $3.73 million in 2025.
Net loss widened to $6.35 million, or $0.60 per share, compared with $5.30 million, or $0.55 per share. Cash and cash equivalents declined to $4.94 million, and operating and investing activities used cash. DSS carries significant debt, including a large medical-facility loan in default, and disclosed substantial doubt about continuing as a going concern despite recognizing an $8.52 million related-party convertible bond investment that lifted total assets and stockholders’ equity.